[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05489783":3,"trial-entities:NCT05489783":134,"trial-summary:NCT05489783":137},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":14,"conditions":16,"keywords":18,"study_type":22,"primary_purpose":14,"phases":23,"enrollment_info":24,"interventions":27,"primary_outcomes":28,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":14,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":122,"overall_officials":126,"references":130,"see_also_links":131},"NCT05489783","22-199","Glioma Developmental and HyperActive Ras Tumor (DHART) Board","RECRUITING","2027-07-31","2026-08","2026-08-31","2022-07-29","Memorial Sloan Kettering Cancer Center","OTHER",null,"This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition.\n\nThis registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.",[17],"Glioma",[19,20,21,5],"NF1-associated glioma","Neurofibromatosis","Registry","OBSERVATIONAL",[],{"count":25,"type":26},50,"ESTIMATED",[],[29],{"measure":30,"description":31,"timeFrame":32},"Registry of patients with Neurofibromatosis Type 1 (NF1) associated glioma","The overarching goal of the registry is to collect baseline and follow-up 1) clinical and 2) imaging data to have a centralized and living repository of information about the adult glioma NF1 patient population.","5 years",[],"ALL","18 Years",false,{"inclusion":38,"exclusion":43,"raw_text":46},[39,40,41,42],"Clinical diagnosis that meets NIH criteria for NF1 disease by either 1) documented clinical record establishing NF1 or 2) self-reported with supported documentation upon medical record collection.","Willing to have historical and future NF1 related health records sent to registry for review.","Radiologic or pathologically confirmed glioma.","Individuals ≥18 years of age on the date of informed consent.",[44,45],"Unwillingness to sign informed consent.","No proficiency in English or Spanish as determined by the Investigator.","Inclusion Criteria:\n\n* Clinical diagnosis that meets NIH criteria for NF1 disease by either 1) documented clinical record establishing NF1 or 2) self-reported with supported documentation upon medical record collection.\n* Willing to have historical and future NF1 related health records sent to registry for review.\n* Radiologic or pathologically confirmed glioma.\n* Individuals ≥18 years of age on the date of informed consent.\n\nExclusion Criteria:\n\n* Unwillingness to sign informed consent.\n* No proficiency in English or Spanish as determined by the Investigator.",[48,49],"ADULT","OLDER_ADULT",[51,65,74,83,93,102,113],{"facility":52,"status":7,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":62},"Memorial Sloan Kettering Basking Ridge (All Protocol Activities)","Basking Ridge","New Jersey","07920","United States",[58],{"name":59,"role":60,"phone":61},"Anna Piotrowski, MD","CONTACT","212-610-0483",{"lat":63,"lon":64},40.70621,-74.54932,{"facility":66,"status":7,"city":67,"state":54,"zip":68,"country":56,"contacts":69,"geoPoint":71},"Memorial Sloan Kettering Monmouth (All protocol activities)","Middletown","07748",[70],{"name":59,"role":60,"phone":61},{"lat":72,"lon":73},40.39428,-74.11709,{"facility":75,"status":7,"city":76,"state":54,"zip":77,"country":56,"contacts":78,"geoPoint":80},"Memorial Sloan Kettering Bergen (All Protocol Activities)","Montvale","07645",[79],{"name":59,"role":60,"phone":61},{"lat":81,"lon":82},41.04676,-74.02292,{"facility":84,"status":7,"city":85,"state":86,"zip":87,"country":56,"contacts":88,"geoPoint":90},"Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)","Commack","New York","11725",[89],{"name":59,"role":60,"phone":61},{"lat":91,"lon":92},40.84288,-73.29289,{"facility":94,"status":7,"city":95,"state":86,"zip":96,"country":56,"contacts":97,"geoPoint":99},"Memorial Sloan Kettering West Harrison (All Protocol Activities)","Harrison","10604",[98],{"name":59,"role":60,"phone":61},{"lat":100,"lon":101},40.96899,-73.71263,{"facility":103,"status":7,"city":86,"state":86,"zip":104,"country":56,"contacts":105,"geoPoint":110},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",[106,107],{"name":59,"role":60,"phone":61},{"name":108,"role":60,"phone":109},"Ingo Mellinghoff, MD","646-888-3036",{"lat":111,"lon":112},40.71427,-74.00597,{"facility":114,"status":7,"city":115,"state":86,"zip":116,"country":56,"contacts":117,"geoPoint":119},"Memorial Sloan Kettering Nassau (All Protocol Activities)","Rockville Centre","11570",[118],{"name":59,"role":60,"phone":61},{"lat":120,"lon":121},40.65871,-73.64124,[123,125],{"name":59,"role":60,"phone":61,"email":124},"piotrowa@mskcc.org",{"name":108,"role":60,"phone":109},[127],{"name":128,"affiliation":12,"role":129},"Anna Piotrowski","PRINCIPAL_INVESTIGATOR",[],[132],{"label":12,"url":133},"https:\u002F\u002Fwww.mskcc.org\u002F",{"nct_id":4,"conditions":135,"biomarkers":136},[17,20],[],{"nct_id":4,"found":138,"summary":139,"prompt_version":149},true,{"design":140,"status":141,"heading":142,"summary":143,"follow_up":144,"word_count":145,"commitments":146,"compensation":147,"drugs_mentioned":148},"This is an observational study aiming to enroll 50 participants. It is not testing a new treatment but rather collecting information to learn more about NF1-associated glioma.","completed","Glioma Developmental and HyperActive Ras Tumor (DHART) Board Registry","This study is creating a registry, which is a collection of health information, for people with a type of brain tumor called NF1-associated glioma (glioma linked to Neurofibromatosis Type 1). Researchers will gather your medical records, scan results, and survey responses over five years. The goal is to better understand how NF1-associated glioma is diagnosed and treated, and how these treatments and the disease affect your quality of life. This study is for adults aged 18 and older who have a clinical diagnosis of NF1 and a confirmed glioma. There are no specific interventions or drugs being tested in this observational study.","Participants will be part of the registry for five years to track their health information.",102,"You would need to agree to have your historical and future NF1-related health records sent to the registry for review. You will also complete surveys.","Not stated in the trial record.",[],"v2"]